BRONX, NY - A state inspection at Riverdale Nursing Home revealed serious lapses in medication monitoring, with staff failing to obtain required blood tests for a resident receiving high doses of an anticonvulsant medication despite multiple reminders from pharmacy consultants.
Critical Medication Monitoring Failure Puts Resident at Risk
The facility's breakdown in basic medication safety protocols centered on Resident #39, diagnosed with Non-Alzheimer's Dementia and Schizoaffective Disorder. This resident was receiving 625 milligrams of Depakote three times daily - a substantial dose totaling 1,875 milligrams per day of this powerful anticonvulsant medication.
Despite the facility's own policies requiring physicians to "address laboratory and other diagnostic test results in a timely manner based on the resident's condition and the clinical significance of the results," staff failed to follow through on critical blood monitoring for this medication. The inspection found that although a pharmacy consultant specifically recommended obtaining serum levels on February 11, 2025, noting they were "unable to locate a recent serum level in the chart," the test was never performed.
The Nurse Practitioner documented agreement with the pharmacist's recommendation on February 12, 2025, stating "Agree Will do" and ordered the blood test for February 13. However, no evidence existed that the serum level was ever drawn, and neither the physician nor nurse practitioner followed up on the missing results.
Medical Risks of Unmonitored Depakote Administration
Depakote (valproic acid) requires careful monitoring through regular blood tests because therapeutic and toxic levels exist within a narrow range. Without proper monitoring, residents face significant health risks including liver damage, pancreatitis, and blood disorders. The medication can also cause excessive sedation, tremors, and cognitive impairment when levels become too high - particularly concerning for a resident already diagnosed with dementia.
Standard medical protocol dictates that Depakote levels should be checked within two weeks of starting the medication, then regularly thereafter - typically every six months for stable patients. The monitoring becomes even more critical when administering higher doses like the 1,875 milligrams daily this resident was receiving. Blood tests help determine whether the medication remains within the therapeutic range of 50-100 micrograms per milliliter, preventing both ineffective treatment and dangerous toxicity.
Systematic Communication Breakdown
The inspection revealed a troubling lack of accountability in the facility's medication management system. When interviewed on March 19, 2025, the Nurse Practitioner stated they "wait for the Registered Nurse to inform them of the laboratory test results" and claimed they were "not notified of the results or the reason why was the serum level not obtained."
This passive approach to critical medication monitoring directly contradicted the facility's own policies, which explicitly state that physicians must periodically review all medications and monitor for possible adverse drug reactions. The Medical Director, when interviewed the same day, acknowledged that "the Nurse Practitioner should have followed up timely when they had not received the laboratory results."
The facility's Laboratory and Diagnostic Test Results policy, revised in January 2025, clearly outlined responsibilities for processing test requisitions and reporting results. It specifically noted that concerns about test result handling "should not prevent timely, clinically appropriate management of a current result or clinical situation." Yet in this case, the absence of any follow-up mechanism allowed a critical safety test to fall through the cracks entirely.
Industry Standards and Best Practices Ignored
Professional standards in long-term care require robust systems for tracking laboratory orders and results, particularly for high-risk medications. Facilities typically employ multiple safeguards including electronic tracking systems, paper logs, and designated staff responsible for following up on pending tests. The complete absence of follow-up for over a month after ordering the Depakote level represents a fundamental failure in these basic safety systems.
For residents with cognitive impairment who cannot advocate for themselves, these monitoring protocols become even more essential. The resident's moderate cognitive impairment and psychiatric conditions meant they likely could not recognize or report symptoms of medication toxicity, making regular blood monitoring the primary method for ensuring their safety.
The pharmacy consultant's role in identifying the missing serum level demonstrates the importance of regular medication reviews. However, the facility's failure to act on this expert recommendation - despite documented agreement from the Nurse Practitioner - highlights a concerning gap between policy and practice that left a vulnerable resident at unnecessary risk for over a month without proper medication monitoring.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Riverdale Nursing Home from 2025-03-19 including all violations, facility responses, and corrective action plans.
💬 Join the Discussion
Comments are moderated. Please keep discussions respectful and relevant to nursing home care quality.